What are ARBs, really?
ARB stands for angiotensin receptor blocker. In the pharmacy you will hear them called sartans, because almost every one of them ends in those letters: losartan (Cozaar), valsartan (Diovan), candesartan (Atacand), telmisartan (Micardis), irbesartan (Avapro), olmesartan (Benicar), azilsartan (Edarbi), eprosartan (Teveten). Spot the suffix and you have spotted the family.
To understand what they do, it helps to know the drug they were designed to improve on. ACE inhibitors — the "-prils" — were already excellent blood pressure medicines, but a chunk of the people taking them developed a stubborn, tickly dry cough that never quite went away. The cough was not a flaw in the dose or the brand. It was baked into how the drug worked. So in the late 1980s, scientists at DuPont asked a different question: instead of shutting down the enzyme that builds the pressure-raising molecule, what if we let the molecule get built and simply blocked the place it needs to dock?
That idea became losartan, the first ARB, approved by the FDA in 1995. The whole class follows the same logic. They reach the same finish line as ACE inhibitors — relaxed blood vessels, lower pressure, a calmer heart — but they get there by a different route, and that one detour is exactly why they usually skip the cough.
The single most useful thing to keep in your head: ARBs and ACE inhibitors are not rivals so much as two doors into the same room.
How they work — the simple version
Your body runs a pressure-control system with a clunky name: the renin-angiotensin-aldosterone system, or RAAS. Picture it as a chain of dominoes. When blood pressure or blood volume drops, the kidneys release renin. Renin kicks off a relay that ends in a powerful molecule called angiotensin II. Angiotensin II is the muscle of the whole system — it clamps down on blood vessels to push pressure up, and it tells the body to hold on to salt and water through a hormone called aldosterone.
Here is the part that matters. Angiotensin II does not act by magic. It has to physically dock onto a receptor — think of it as a keyhole on the surface of your blood vessel cells. The main keyhole is called the AT1 receptor. When angiotensin II turns that lock, the vessel squeezes and the pressure climbs.
ACE inhibitors stop angiotensin II from being manufactured in the first place — they jam the assembly line a step early. ARBs leave the factory running. Instead, they plug the keyhole. An ARB is a key-shaped impostor: it slides perfectly into the AT1 lock, fills the slot, but refuses to turn. Angiotensin II is still floating around in the bloodstream, banging on the door, but it cannot get in. No turn of the lock, no squeeze. The vessel stays relaxed and the pressure eases.
Two consequences fall straight out of this design.
First, less cough. The ACE enzyme has a side job: it also breaks down a molecule called bradykinin. Block the enzyme and bradykinin piles up in the lungs, which is what tickles off that famous dry cough. ARBs do not touch the ACE enzyme at all, so bradykinin is handled normally. Less bradykinin buildup explains the lower cough risk; cough can still occur. The same reasoning explains why the dangerous swelling reaction called angioedema, which is partly bradykinin-driven, is much rarer with ARBs.
Second, there is a small bonus. Angiotensin II that cannot reach the blocked AT1 keyhole drifts over to a different one, the AT2 receptor, which ARBs leave wide open. The AT2 receptor tends to do the opposite of AT1 — it nudges vessels to relax rather than tighten. So some of the redirected angiotensin II may actually help. It is a tidy bit of biology: block the harmful door, leave the helpful one ajar.
What else they do to your body, beyond lowering blood pressure
Turn down the RAAS and a few predictable things follow. None of these are surprises — they are the same trade-offs the system makes whether you block the factory (ACE inhibitor) or block the door (ARB). The mechanism is what it is.
First-dose dizziness. If you are already low on fluid — dehydrated, recently sick, or taking a strong water pill (loop diuretic) — your body may be leaning hard on angiotensin II just to keep pressure up. Knock out that prop suddenly and the pressure can dip more than expected, leaving you lightheaded. This is why the first few doses deserve a little caution rather than a casual shrug.
Potassium creeping up. Less angiotensin II means less aldosterone, and aldosterone is the hormone that tells your kidneys to dump potassium into the urine. Dial it down and potassium can build up in the blood — a state called hyperkalemia. Usually mild, occasionally dangerous, which is why a blood test is part of the deal.
The kidneys. Angiotensin II helps fine-tune the plumbing inside each kidney. In most people, easing that pressure is fine or even protective. But in someone whose kidney arteries are both badly narrowed (bilateral renal artery stenosis), the kidneys depend on that angiotensin II pressure to keep filtering. Remove it and filtration can crash. For that reason, narrowing of both kidney arteries is an absolute reason not to use these drugs — exactly as it is for ACE inhibitors.
Pregnancy. This is a hard line. ARBs can seriously harm a developing baby, especially in the second and third trimesters, by damaging fetal kidneys. They are contraindicated in pregnancy, full stop. Anyone who could become pregnant should have that conversation with their clinician before starting.
And the headline difference from ACE inhibitors, worth repeating because so many people get it wrong: ARBs are much less likely to cause the dry cough, because they leave bradykinin alone. Angioedema is possible but rare. One genuine quirk worth a footnote — telmisartan moonlights as a partial activator of a metabolic switch called PPAR-gamma, the same target some diabetes drugs hit. It is unique in the class for this, and it may offer a small extra metabolic nudge in people with type 2 diabetes, though it is not why anyone is prescribed it.
What people usually take with them, and why
ARBs are not a niche fallback. Major guidelines list them as a genuine first-line choice, and a stack of landmark trials explains where each one earned its stripes.
High blood pressure. The 2018 European guidelines (Williams et al., European Heart Journal) put ARBs among the core first-line drug classes for hypertension, on equal footing with ACE inhibitors. They are an obvious pick for anyone who could not tolerate an ACE inhibitor, but they do not need that excuse to be chosen.
Diabetic kidney disease. This is where ARBs really shine. Two trials published back-to-back in 2001 settled it. In RENAAL, losartan slowed the slide toward kidney failure in people with type 2 diabetes and protein in the urine, beyond what its blood-pressure effect alone could explain (Brenner et al., NEJM). In IDNT, irbesartan did the same and outperformed a calcium-channel blocker for kidney protection (Lewis et al., NEJM). Together they made ARBs a default tool for protecting diabetic kidneys.
Heart and stroke protection. The LIFE trial pitted losartan against an older beta-blocker, atenolol, in people with high blood pressure and a thickened heart muscle. Losartan came out ahead, cutting strokes more effectively (Dahlöf et al., Lancet, 2002). For comparison with the class it beat, that was a notable result.
Heart failure. When someone with heart failure cannot tolerate an ACE inhibitor, candesartan stepped in and reduced deaths and hospital admissions in the CHARM-Alternative trial (Granger et al., Lancet, 2003). After a heart attack complicated by heart failure, valsartan held its own against the established ACE inhibitor captopril in VALIANT, proving as good rather than worse (Pfeffer et al., NEJM, 2003).
The newer twist — ARNIs. You may have heard of Entresto. It is not simply a fancier ARB. It is a combination, an ARNI: valsartan (the ARB) bolted to sacubitril (a neprilysin inhibitor), a completely separate mechanism that boosts the body's own pressure-relieving peptides. In the PARADIGM-HF trial, this combination beat the ACE inhibitor enalapril at reducing death and hospitalization in heart failure with a weak pump (McMurray et al., NEJM, 2014). The 2021 European heart failure guideline now favours an ARNI over a plain ACE inhibitor or ARB for many of these patients (McDonagh et al., European Heart Journal).
A few combinations to be aware of, because they change the math:
- NSAIDs (ibuprofen, naproxen, diclofenac) plus an ARB plus a water pill is the "triple whammy" — three drugs ganging up on the kidneys at once, the same trap ACE inhibitors fall into.
- Potassium-sparing diuretics and potassium supplements push potassium higher, and ARBs are already nudging it up. The two together can tip into dangerous territory.
- Lithium levels rise when an ARB is added, and lithium has very little safety margin to spare.
- Another ACE inhibitor. The big one. The ONTARGET trial tested whether stacking telmisartan on top of ramipril — blocking both the factory and the door — was better than either alone. It was not. The combination brought more low blood pressure and more kidney trouble with no survival payoff (Yusuf et al., NEJM, 2008). Routine dual RAAS blockade is not recommended.
Red flags — when to call a doctor
If you are on an ARB, these are not "wait and see" symptoms. They are reasons to pick up the phone or, in a couple of cases, head to the emergency room.
- Severe dizziness or fainting, especially in the first days or after a dose, and especially if you have been dehydrated or are on a strong water pill — your pressure may have dropped too far.
- Swelling of the face, lips, tongue, or throat, or sudden trouble breathing — this is angioedema. It is rare with ARBs, but it is an emergency. Stop the drug and get to the ER.
- A noticeable drop in how much you are urinating in the first weeks — possible warning of a kidney-artery problem the drug has unmasked.
- Palpitations, muscle weakness, or a strange heaviness in your limbs — these can be signs of potassium climbing to a dangerous level.
- Pregnancy, or finding out you are pregnant. This needs an immediate change of plan with your clinician — do not wait for the next routine appointment.
One more, quieter rule: do not stop an ARB abruptly on your own. If something feels wrong, that is a conversation with a doctor or pharmacist, not a solo decision. Blood pressure that was being held in check can rebound when the medicine vanishes overnight.
What people get wrong
"ARBs are just the weaker version of ACE inhibitors." Not according to the head-to-head data. In ONTARGET, telmisartan held its own against ramipril for major cardiovascular outcomes — it was non-inferior, not second-best (Yusuf et al., NEJM, 2008). Different door, same room.
"I coughed on an ACE inhibitor, so I'll cough on an ARB too." This is the most common mix-up, and it is backwards. The cough comes from bradykinin piling up, and only ACE inhibitors cause that buildup. ARBs leave bradykinin alone, so they almost never cause the cough. The one exception worth flagging to a doctor is if you had true angioedema (the dangerous swelling) on an ACE inhibitor — then switching deserves caution, not a casual swap.
"ARBs don't protect the kidneys as well." RENAAL and IDNT say otherwise. Both showed real kidney protection in people with type 2 diabetes and protein in the urine, beyond blood pressure alone (Brenner et al.; Lewis et al., NEJM, 2001). This is arguably their strongest single credential.
"No need to check labs once I'm on an ARB." Same monitoring as ACE inhibitors applies: kidney function (creatinine) and potassium after starting or changing the dose, then periodically. The drug is quiet, but the labs are how you keep it that way.
"Entresto is basically just an upgraded ARB." It is an ARNI — valsartan paired with sacubitril, a neprilysin inhibitor. That second ingredient works through an entirely separate pathway. Calling it a fancy ARB misses the whole point of why it outperformed an ACE inhibitor in PARADIGM-HF (McMurray et al., NEJM, 2014).
"Take an ARB and an ACE inhibitor together for double the effect." ONTARGET tested exactly this and found more harm — low blood pressure, acute kidney injury — with no survival benefit (Yusuf et al., NEJM, 2008). Doubling the block does not double the good.
"ARBs are only for people who can't handle ACE inhibitors." They are a first-line choice in their own right — for high blood pressure, for diabetic kidney disease, for heart failure. Being ACE-intolerant is one reason to pick an ARB. It is far from the only one.